Founded in 1993, the Sino-American Pharmaceutical Professionals Association (SAPA) grew rapidly and has become one of the most active and well-recognized Chinese-heritage enduring professional organizations in the United States. SAPA is an independent, nonprofit and professional organization with over 6,000 members in USA, China, Hong Kong, Taiwan and Japan. Its headquarters is based in the tri-state area (NY-NJ-CT) with six regional chapters in New England, Greater Philadelphia and California bay area, and one chapter in Shanghai, China.
The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix aspires to foster and create business opportunities, supply and nurture leaders for the community, and network and share information and experience among its members. The diverse membership base covers many of the world’s top pharmaceutical and biopharmaceutical companies, leading professional services and investment firms, as well as start-up biotech companies in China and the US. BayHelix membership is by-invitation only. Over two thirds of members are C-level executives. The majority of them are cross trained in science and business as well as bilingual in Chinese and English. BayHelix has become an influential organization that connects emerging biopharmaceutical companies in China to their counterparts around the world.
The Chinese Biopharmaceutical Association-USA (CBA) is one of the largest Chinese American professional associations in the US founded in 1995. CBA is an independent, non-political, and non-profit professional organization headquartered in the Washington DC area. The membership now comprises more than 3,000 biopharma-related professionals from industry, academia, and government. Over 80 percent of the members hold Ph.D., M.D. and/or J.D. degrees. CBA also has over one hundred Institutional Members. The mission of CBA is to promote communication and collaboration among biopharmaceutical professionals and to promote technology transfer and business collaborations between the United States and China.
Korea Biotechnology Industry Organization (KoreaBIO) is an association established as result of merger between three different industry associations in the biotechnology field in November 2008.
KoreaBIO promotes communication among all bio-industry related organizations and is striving to create a sustainable biotechnology industry ecosystem.
KoreaBIO is central organization with around 500 members from major pharma & biotechnology enterprises to special members, representing the biotechnology industry of Korea. KoreaBIO also develops various training and policy-making programs to serve the member companies more efficiently and promotes co-operation, investment relations, and technological collaborations around the world.
2014年2月，一个非营利性专业机构：BiG生物医药创新社（Biologics Innovation Group）在充满药味的上海张江应运而生，旨在为中国生物医药行业的发展创造一个滋养原创的生态环境。BiG 持续坚持非营利机制；坚持“会员所有、会员自治、服务会员“（Of member, by member, for member）的治理原则。六载春秋，从成立之初的21人，日渐壮大已成长拥有400余位个人会员、20家企业会员的生物医药创新社群。
雅法全球医疗（YAFO Life Science）是雅法资本旗下的医疗大健康部门。专注于帮助中国创新药企业达成海内外市场授权、股权融资、产品交易、及提供寻找和引进海外标的服务；同时协助具有“中国角度”的海外医药企业在中国的授权、战略合作及融资。我们致力于成为全球医疗技术对接中国市场与资本的桥梁。目前海外有超过三十位资深合伙人，深度覆盖美国、欧洲、日本、韩国等全球医疗创新区域。雅法全球医疗专注以下业务：
The New Drug Founders Club was founded in April, 2015, to form a network for founders of companies focusing on innovative new drug R&D and of companies providing relevant services. The club is highly prestigious in that only founders of such companies and people well-recognized for having special and major contributions to new drug R&D in China (including China R&D heads of multinational companies, R&D heads of major domestic companies, partners of VC, and other nationally recognized leaders in new drug R&D) can be admitted to the club. This feature distinguish this club from any other professional organizations in China or the world.
新药创始人俱乐部（New Drug Founders Club)于2015年3月27日成立，是一个汇集新药研发创业者，以分享经验，互相帮助为主要形式，秉承“创新、务实、分享、成长”理念，推动国家新药研发事业为目的的非营利性的企业家服务机构。俱乐部专注于新药邻域的创业者，已在中国树立了品牌并具有良好的会员粘性。通过会员资源的主动聚集，逐步搭建起“智库平台”、“媒体渠道”、“融资平台”，为会员创业及公司发展提供实质性的帮助。俱乐部目前拥有个人会员330位，企业会员2家，均为新药研发公司，新药CRO、新药技术平台创始人，生物医药基金创始人或负责人，或对中国创新药事业有杰出贡献或影响力的人士，其中有70余位会员为国家级重大人才引进工程，现有上市企业20余家。